FONAR Corporation

NASDAQ:FONR

Medical - Devices

Healthcare
$19.09 +0.00%

+$0.00 today

Market cap
$117.76M
Beta
0.95
P/E (TTM)
17.6
EPS (TTM)
$1.08
52W Low $13.62High $19.16

Volume 0.00M

Average 0.08M

FONR Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

FONAR CorporationNASDAQ: FONR

Capital Expenditures · Q3 FY2026 · quarter ended Mar 2026

Capital expenditures declines year over year

Q3 FY2026 capital expenditures of $171K (cash outflow) fell 71.2% year over year, behind the -13.8% change in trailing-twelve-month capital expenditures. Sequentially, it fell 57.0% from the prior quarter. Over 3 fiscal years it compounded at -6.3% a year.

Context

  • Capital expenditures amounted to 3.7% of revenue in FY2025, up 2.9 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -71.2% toward the trailing-twelve-month pace of -13.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$171K-57.0% QoQ
Last fiscal yearJun 2025
-$3.82M+363.9% YoY
LTMMar 2026
-$3.08M-13.8% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-71.2%——
1 year+363.9%——
3-year CAGR-6.3%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(3.82M) USD
Year-over-year change
-363.9%

Capital Expenditures vs competitors

How FONR compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13.8% is the 7th highest of 8, against a peer median of +102.5%.
  • Capital expenditures amounts to 2.9% of revenue for FONR, versus a peer median of 2.0%.
FONR Competitors
Capital Expenditures for FONR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FONRFONAR CorporationLTM Mar 2026$3.08M USD-13.8%-6.3%2.9%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$2.32M USD+104.2%-25.7%—
VANIVivani Medical, Inc.LTM Mar 2026$1.17M USD+209.0%+51.4%—
APYXApyx Medical CorporationLTM Mar 2026$1.12M USD+50.8%+3.3%2.0%
HYPRHyperfine, Inc.LTM Mar 2026$955K USD+34.5%+26.5%6.2%
RCELAVITA Medical, Inc.LTM Mar 2026$212K USD+102.5%+49.1%0.3%
LUNGPulmonx CorporationLTM Mar 2026$160K USD-87.7%-30.0%0.2%
IFRXInflaRx N.V.LTM Mar 2026€114.87K EUR+178.5%-11.9%391.6%
Peer median (excluding FONR) —+102.5%+3.3%2.0%

Competitors are the stored peer set for FONR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income13.67M17.23M12.13M14.1M10.67M
Depreciation & Amortization5.54M8.54M8.8M4.6M4.7M
Deferred Income Tax3.53M3.09M2.98M2.8M823.66K
Stock-Based Compensation83.28K0000
Change in Working Capital(11.26M)(14.21M)(15.17M)(8.62M)(8.19M)
Accounts Receivables(11.91M)(5.56M)(8.12M)(11.62M)(8.98M)
Inventory(14.65K)(696.4K)(209.85K)(145.78K)(97.24K)
Accounts Payables(99.22K)(314.77K)19.69K276.67K(553.56K)
Other Working Capital762.59K(7.64M)(6.86M)2.87M1.44M
Other Non-Cash Items7.53M642.77K5.73M1.22M3.26M
Operating Cash Flow19.09M15.3M14.47M14.09M11.26M
Capital Expenditures(4.82M)(4.63M)(4.34M)(822.85K)(3.82M)
Acquisitions (Net)0(546K)000
Purchases of Investments(293)(149)(473)(103.3K)0
Sales of Investments00000
Other Investing Activities(163.71K)(87.88K)(119.57K)42.53K(9.72K)
Investing Cash Flow(4.82M)(5.18M)(4.34M)(850.74K)(3.8M)
Debt Repayment(40.34K)(37.24K)(36.62K)(44.9K)(113.94K)
Common Stock Issued00000
Common Stock Repurchased00(1.76M)(2.51M)(1.81M)
Dividends Paid00000
Other Financing Activities(6.57M)(5.82M)(5.78M)(5.63M)(5.55M)
Financing Cash Flow(6.61M)(5.86M)(7.57M)(8.18M)(7.47M)
Effect of Forex Changes00000
Net Change in Cash7.66M4.26M2.56M5.06M(7.56K)
Free Cash Flow14.27M10.67M10.13M13.27M7.45M

FONAR Corporation

NASDAQ:FONR

Intrinsic Alpha fair value

Locked

Current Price

$19.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.